Leukapheresis
Leukapheresis - Related Videos
08:40
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
0 Views •
Cited by 20 •
2013
The most commonly used method for generating large numbers of autologous dendritic cells (DCs) for use in tumor immunotherapy is described. The method uses IL-4 and GM-CSF to differentiate DCs from monocytes. The immature DCs are stimulated to mature and then loaded with antigens before they are injected back into the patient.
06:46
Culture of Macrophage Colony-stimulating Factor Differentiated Human Monocyte-derived Macrophages
0 Views •
Cited by 66 •
2016
A protocol is presented for cell culture of macrophage colony-stimulating factor (M-CSF) differentiated human monocyte-derived macrophages. The protocol utilizes cryopreservation of monocytes coupled with their bulk differentiation into macrophages. Then harvested macrophages can then be seeded into culture wells at required cell densities for carrying out experiments.
FAQs
The machine uses either centrifugation or filtration to distinguish the leukocyte-rich fraction from the rest of the blood. It directs that selected fraction into a collection pathway while preserving red blood cells, platelets, and plasma for return to the patient. This component-selective design allows white-cell reduction without removing the entire blood volume.
Returning the non-target blood components limits the procedure to its intended cellular effect: reducing circulating leukocytes. Red blood cells, platelets, and plasma remain available to continue their normal roles after processing. This approach also supports continuous blood circulation through the machine rather than collecting all processed blood outside the patient.
In acute leukemia with hyperleukocytosis, a dangerously high leukocyte count can create urgent complications. Leukapheresis can reduce the circulating leukocyte burden rapidly, helping limit those complications while definitive treatment takes effect. Its role is therefore time-sensitive and supportive, providing a temporary reduction rather than replacing treatment directed at the underlying leukemia.
The immediate goal determines how the procedure is used. In a clinical reduction setting, the leukocyte-rich fraction is removed to lower an excessive circulating count. In another application, leukapheresis may support collection or preparation of specific blood-cell products for therapeutic use. Thus, the same component-separation principle can serve patient management or product preparation.
Blood is taken from the patient through the venous system and processed continuously by an apheresis machine. The device separates the components, directs the leukocyte-rich fraction to collection, and returns the remaining blood components through the venous system. The workflow is designed to maintain circulation while selectively processing the targeted white-cell fraction.
A key medical use is acute leukemia accompanied by hyperleukocytosis, when a rapid reduction in circulating leukocytes may help limit associated complications. The procedure can act while definitive treatment takes effect, making it a supportive intervention in an urgent setting. It may also be used when specific blood-cell products need to be collected or prepared for therapeutic use.